• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Blog
  • News & Events
  • Videos
  • Resources
main-logo-small

Compliance Architects

Consulting Technology Outsourcing

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Batch Failures: Significant Risk Events; Challenging Investigation Opportunities

Today’s (4/25/2012) news from In-Pharmatechnologist.com (see full link below) highlights information from FDA’s 2011 Warning Letter dataset.   The article states that:

“In fiscal 2011 the US Food and Drug Administration (FDA) sent biopharma manufacturing-related warning letters to 52 facilities. Close to half of these included an observation about failure to thoroughly investigate batch failure.”

The article goes on to state that:

“The finding reiterates the point, made by FDA speakers at industry conferences, that companies should clearly and thoroughly document their procedures and activities. Other companies were warned last year for lacking written rules for investigating out-of-specification results.”

Looking at the observations cited and considering the FDA speakers’ comments, this would seem to be a reasonably easy issue to resolve.   How hard can it really be to look at what happened during the execution of a batch (i.e, by reviewing the batch record) and determine what happened?   How hard can it be to document procedures and activities for batch execution?    Doesn’t everyone know how to investigate anomalous results?

Oh, were things so simple.

The reality of batch failures, and batch failure investigation, is much more complicated.   Some existing documents don’t help.  Some investigation approaches are often superficial.    Getting to true root cause (no, I mean TRUE root cause) is often neglected, frankly, because it’s very difficult to do.  Given that good investigations may not be as simple as having “rules for investigating out-of-specification results,”  let’s look at two areas that are often not considered in batch failure investigation resolution.

SPECIFICATIONS

Specification review and analysis should be at the core of good investigations.   The question we often ask is:  why did our batch fail to meet specifications?   We try to find reasons related to subpar raw materials, poor execution, different processing, etc. that made the batch react differently.    We never question our specifications since to do so during an investigation, when product is in play, is a huge red-flag for an FDA Investigator .    The FDA immediately  assumes that financial considerations drove the thinking, and that leads to uncomfortable conversations.

Unfortunately, though the question that is almost never asked outside of an investigation is:   Do our specifications align to our process capability?   In other words, do we have specifications that are disconnected from our process capability?   The answer to this question is critical for a company to understand.  More importantly, a company’s failure to understand the linkage between specifications and process capability is something I’ve seen over and over again as one of the true root causes of batch failures.   Put more simply:  When companies set release specifications that are too tight — essentially using specifications for process management / process control purposes — unless your processes are highly-capable and well controlled — you create the significant risk of failing to meet your specifications, when in fact, you may only be experiencing routine process control variation.

Remember:   the FDA doesn’t create your specifications — you do.   You create the box which you need to live within.   Using specifications for process control leads to many more failures than are necessary.  Many more NCs.  Many more CAPAs.   Specifications should be at the boundary beyond which a company will not release product.  Everything inside of that line should be evaluated and considered through control limits, subject to either monitoring, action, or review and decision.   Specifications, though, should be binary.    Batches either pass or they don’t.   Using well defined specifications with well-understood control limits tied to robust product and process characterization will prevent batch failures, but more importantly save time, energy, and MONEY!

BATCH RECORDS AND CRITICALITY

Here’s an opening question:   What is the intended purpose of a batch record?    Answer:   A batch record is intended (by FDA) to provide a documented record of the steps, activities and accompanying data (whether from in-process testing, weigh steps, process parameter settings, etc) that constitute the entire manufacturing record of a pharmaceutical batch’s manufacture.   See 21 CFR 211.188(b).

In essence, a batch record is a key compliance tool to document that a defined process was followed in the production of the batch.    Note that I didn’t say that the batch record was a quality tool.    Why not?    Simply because most batch records don’t provide nearly sufficient information — differentiated information — regarding the one or two key steps in almost any process that if done properly, result in a “good” batch of product, and if done improperly (or something else goes wrong) result in a sub-standard or failed batch of product.

If you look at a batch record, or watch QA people audit and review batch records, each step in the end-to-end process appears equally important.  There is never (well, almost never) any differentiation with respect to criticality or importance.  There is no explanation of linkage to poor step outcomes and overall batch quality.    Further, the tricks and tips that the super-operators use to always get batches perfect, are almost never incorporated into the record.    Why not?   Well, that’s a good question.  It’s likely that it’s just the way it’s always been — our record formats and structure are often derived from legacy products — potentially very old products.   However, that needs to change.    Batch quality is almost always defined by perfect execution of the 20% of steps and activities that are most critical to the quality outcome.  Most everything else — material handling operations, weigh steps, label recording, etc. are oriented towards things like potency and mix-up prevention, admittedly important topics.   But the factors — the steps — the precise activities that have big impacts on characteristics like disintegration, dissolution, bioavailability, etc., are often buried in a much larger step, and often, not well differentiated.

So, back to the original topic:   Industry’s failure to properly investigate batch failures.      Even considering just the two foregoing areas of focus, it is easy to see that developing exceptional (or even just plain good) batch failure investigations is extremely hard work.    There are of course other factors:   Time, number of resources, production pressures, etc. — the list goes on and on.   However, given the focus and clear enforcement tsunami this topic has created, industry should seize the opportunity to look past traditional approaches to specifications, batch and investigation documentation and create new, more rational, more differentiated, and easier to investigate document sets.    Necessary for this is improved product and process characterization and an improved ability to explain what is really happening in batch production — and the occasional failure.   Together, this should result in better interactions with the FDA, and very likely, a reduced cost footprint due to reduction in out-of-spec product and associated investigation costs.

For further information on this or related topics, please contact the author at john.garvey@compliancearchitects.com.

LINKS TO ORIGINAL ARTICLE: 

Half of FY11 FDA GMP warning letters tied to batch failures

Half the pharma firms sent FDA GMP warning letters sent fiscal 2011 were criticised for failing to thoroughly investigate the failure of a batch.

http://www.in-pharmatechnologist.com/Regulatory-Safety/Half-of-FY11-FDA-GMP-warning-letters-tied-to-batch-failures

Filed Under: Achieving Compliance, Quality Management & Assurance

Primary Sidebar

Sign Up To Our Newsletter

You May Also Like

Sue Soderholm to be a Featured Speaker at the 1st Annual Quality Management vSummit – “Optimizing Your Quality Management Program to Be Both World Class and FDA-Compliant” | Tuesday, October 11, 2022 – Wednesday, October 12, 2022

Achieve True Quality Culture and Stay Compliant If your quality management system (QMS) isn’t world class, you may be falling behind. You need the 1st Annual
life sciences staffing

Talk to us about current talent trends, and what the industry will need in the next 5 to 10 years?

Transcript taken from 2022 PMWS by Executive Platforms The talent crisis as it has been called is certainly not something that has gone away or

Preparing for an FDA Pre-Approval Inspection (PAI) – “Begin with the End in Mind.”

Presented by: Teresa Gorecki, Practice Lead, Compliance Architects What is it Steven Covey said in “The 7 Habits of Highly Effective People?” “Begin with the

Footer

Compliance Architects®

  • Contact Us
  • (888) 734-9778
  • info@compliancearchitects.com

Quick Links

  • About Us
    • Senior Staff
    • Why Us
    • Mission And Vision
    • Clients
    • Partners
    • Career Opportunities
  • Services
    • Inspection Readiness & Enforcement
      • FDA Inspection Readiness
      • Audits & Assessments
      • FDA Enforcement Response/Remediation
    • FDA Quality Consulting
      • Quality System & Compliance Turnarounds / Restructuring
      • Training / Coaching
      • Quality & Compliance Computer-Based Systems
      • External Supply Chain Compliance
      • Part 11 & Computer Systems Validation
      • Turnkey Quality Systems
    • Quality Assurance and Engineering
      • CRPN Quality Roadmap®
      • Quality Culture Assessment
      • Product Quality Consulting
      • Operational Efficiency/Compliance Effectiveness
      • Project/Program Management
    • Corporate Compliance and Litigation
      • Corporate Compliance Programs
      • Interactions With Department Of Justice And The Courts
    • FDA Regulatory Consultants
      • Product Development / Submissions / Commercialization
      • REMS (Risk Evaluation And Mitigation Strategies)
      • Mergers / Acquisitions / Licensing
    • Quality, Compliance, Regulatory & Operations’ Staffing
      • Staffing
      • Talent Management
      • Rapid Turnaround
  • Innovative Solutions
    • Writing for Compliance®
    • CRPN Quality Roadmap®
    • Quality Pulse®
    • IEEP
    • REMS
  • Success Stories
  • Industries
    • Biopharmaceuticals
    • Cannabis/CBD
    • Cell & Gene Therapies
    • Combination Products
    • Cosmetics
    • Dietary Supplements
    • Medical Devices and Diagnostics
    • Pharmaceuticals
  • Contact Us

Our Services

  • Inspection Readiness & Enforcement
  • FDA Quality Consulting – Systems and Training
  • Quality Assurance and Engineering
  • Corporate Compliance and Litigation Services
  • FDA Regulatory Consultants – Due Diligence
  • Quality, Compliance, Regulatory & Operations’ Staffing Services

Proprietary Solutions

  • Writing for Compliance®
  • Quality Pulse®
  • CRPN Quality Roadmap®

© 2009-2023 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.

  • Debarment Certification Statement
  • Privacy Policy
  • Terms of Use

Contact Us Today

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT